Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®

Trial Profile

A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CLARIFY MS
  • Sponsors Merck KGaA
  • Most Recent Events

    • 05 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 11 Jun 2018 Planned initiation date changed from 25 Apr 2018 to 15 Jun 2018.
    • 24 Apr 2018 Planned End Date changed from 30 Dec 2021 to 25 Nov 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top